|
|
|
| Treatment of myasthenia gravis based on the theory of "hidden pathogen" |
| RAN Weizheng1 YUE Xifeng2 GAO Fang3 LI Nannan3 LIU Jialin4 ZHANG Xinning1 WANG Yao1 CHEN Zhigang3 |
1.Beijing University of Chinese Medicine, Beijing 100029, China;
2.TCM Department, Shenzhen Longhua District Central Hospital, Guangdong Province, Shenzhen 518110, China;
3.NO.1 Neurology Department, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, China;
4.NO.3 Neurology Department, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, China |
|
|
|
Abstract Myasthenia gravis (MG) is a kind of acquired autoimmune disease with neuromuscular junction transmission disorder, which is always characterized by insidious onset. It is progressive or develops alternately with remission and recurrence, and can be induced or aggravated by infection, fatigue and other factors. Combined with the discussion of related symptoms of MG in the ancient literature and the modern researches, it is believed that hidden pathogen plays an important role in the pathogenesis of MG. Therefore, in the treatment of MG, on the basis of supplementing deficiency, attention should be paid to the differentiation and treatment of hidden pathogen. In the acute stage, reinforcing deficiency shouled be paid equal attention with eliminating pathogenic factors. In the remission stage, gradually reduce eliminating pathogenic factors while increase efforts to reinforcing deficiency. Reinforcing deficiency mainly benefits spleen and kidney, while eliminating pathogens is given different treatment methods according different factors: pathogenic toxin, heat, dampness, phlegm and blood stasis.
|
|
|
|
|
|
[1] 何绍奇.论伏邪[J].中国医药学报，1986（3）：8-10.
[2] 任继学.“伏邪”探微（下）——杂病伏邪[J].中国中医药现代远程教育，2003，1（2）：8-9.:
[3] 赵进喜.伏气发病学说对中医现代临床的重要启示[J].中国中医药现代远程教育，2006，4（7）：33-35.
[4] 陈颖霖.头痛宁治疗风寒瘀阻型偏头痛临床研究[D].北京：北京中医药大学，2011.
[5] 赵雪松，樊永平.从伏邪学说探讨多发性硬化的治疗思路[J].北京中医药，2018，37（1）：66-69.
[6] 清·黄朝坊.金匮启钥[M].长沙：湖南科技出版社，2000：980.
[7] 宋·许叔微.普济本事方[M].上海：上海科学技术出版社，1959：77.
[8] 明·张介宾.类经[M].北京：中国医药科技出版社，2011：325.
[9] 董秀娟.重症肌无力中医证治的文献资料整理研究[D].广州：广州中医药大学，2012.
[10] 隋·巢元方.诸病源候论[M].沈阳：辽宁科学技术出版社，1997：134.
[11] 清·汪宏.望诊遵经[M].上海：上海科学技术出版社，1959：52.
[12] 宋·杨士瀛.仁斋直指方论[M].福州：福建科学技术出版社，1989：495.
[13] 元·王履.医经溯洄集[M].北京：人民卫生出版社，1993：8-15.
[14] 清·李用粹.证治汇补[M].太原：山西科学技术出版社，2011：274.
[15] 清·叶天士.临证指南医案[M].北京：华夏出版社，1995：393.
[16] 中华医学会神经病学分会神经免疫学组，中国免疫学会神经免疫学分会.中国重症肌无力诊断和治疗指南2015[J].中华神经科杂志，2015，48（11）：934-940.
[17] Yamamoto AM，Gajdos P，Eymard B，et al. Anti-titin antibodies in myasthenia gravis：tight association with thymoma and heterogeneity of nonthymoma patients [J]. Arch Neurol，2001，58（6）：885-890.
[18] Romi F，Aarli JA，Gilhus NE. Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features [J]. Eur J Neurol，2007，14（6）：617-620.
[19] Romi F，Skeie GO，Aarli JA，et al. Muscle autoantibodies in subgroups of myasthenia gravis patients [J]. J Neurol，2000，247（5）：369-375.
[20] Willcox N，Schluep M，Ritter MA，et al. The thymus in seronegative myasthenia gravis patients [J]. J Neurol，1991，238（5）：256-261.
[21] 张建良，卢芳国.清热解毒中药免疫调节作用的研究进展[J].中医药导报，2012，18（12）：87-89.
[22] 岳喜峰.基于伏邪理论治疗MG的临床研究[D].北京：北京中医药大学，2017. |
|
|
|
